D-0394-2026 Class II Ongoing

Recalled by New Life Pharma LLC — Northvale, NJ

FDA drug recall D-0394-2026 was initiated by New Life Pharma LLC on Feb 26, 2026 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing. Affected quantity: 23 vials.

Recall details

Product Type
Drugs
Report Date
Mar 11, 2026
Initiation Date
Feb 26, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
23 vials

Product description

Tirzepatide Inj, 10mg, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-03.

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

OH

Code information

Lot 240709, exp 7/31/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0394-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0394-2026. Report a data issue: hello@regdatalab.com.